

Antelope Announces Phase 1/2 First-in-Human Study of Investigational Fluorescent Imaging Agent in Prostate Cancer

Enrollment and dosing underway in study of investigational PSMA-targeted fluorescent agent for prostate cancer.



Bringing Light to Cancer

NEW YORK, NY, UNITED STATES, August 13, 2026 /EINPresswire.com/ --

[Antelope](#), a clinical-stage biotechnology company developing targeted fluorescent radioligand technologies for cancer, today announced that enrollment and dosing are underway in its Phase 1/2 first-in-human study of AS1986NS, an investigational PSMA-targeted fluorescent imaging agent for prostate cancer.

“

Bringing our first clinical candidate into human evaluation represents years of work by our team.”

Amy Wu, MD, FACS, Founder and CEO, Antelope

The study is evaluating the safety of AS1986NS and assessing its ability to selectively bind to and produce localized fluorescence in PSMA-expressing prostate cancer cells, with pathology serving as the reference standard. The study is being conducted under an active U.S. Food and Drug Administration Investigational New Drug application.

"Bringing our first clinical candidate into human evaluation

represents years of work by our team," said Amy Wu, MD, FACS, Founder and CEO of Antelope. "We are grateful to the patients participating in this study and to the investigators and clinical teams making this research possible."

About AS1986NS

AS1986NS is an investigational PSMA-targeted fluorescent imaging agent being studied in prostate cancer. It is the lead clinical candidate from Antelope's fluorescent radioligand platform, which combines molecular targeting with fluorescence and is being developed for applications in cancer imaging and treatment.

AS1986NS is investigational and has not been approved by the U.S. Food and Drug

Administration. Its safety and effectiveness have not been established.

About Antelope

[Antelope Surgical Solutions, Inc.](https://www.antelopesurgical.com), operating as Antelope, is a New York-based clinical-stage biotechnology company developing targeted fluorescent radioligand technologies to make cancer more visible. Antelope is developing its platform for applications in cancer imaging, precision surgery, and radioligand therapy. For more information, visit www.antelopesurgical.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding Antelope Surgical Solutions, Inc., including statements concerning its clinical development programs, product candidates, regulatory activities, and future plans. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied.

Forward-looking statements include statements regarding the progress, timing, enrollment, and results of clinical studies; the development and potential applications of AS1986NS and Antelope's technology platform; regulatory activities; and future research, development, strategic, or commercialization activities.

Clinical development involves substantial risks and uncertainties. Results from early clinical studies may not predict results from later or larger studies, and investigational products may not demonstrate safety or effectiveness or receive regulatory approval.

Forward-looking statements speak only as of the date of this release. Antelope undertakes no obligation to update these statements except as required by applicable law.

Antelope PR
Antelope Surgical Solutions
[email us here](#)

Visit us on social media:
[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/933912230>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.